MA27500A1 - PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - Google Patents

PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE

Info

Publication number
MA27500A1
MA27500A1 MA28329A MA28329A MA27500A1 MA 27500 A1 MA27500 A1 MA 27500A1 MA 28329 A MA28329 A MA 28329A MA 28329 A MA28329 A MA 28329A MA 27500 A1 MA27500 A1 MA 27500A1
Authority
MA
Morocco
Prior art keywords
inhibitor
alzheimer
disease
prevention
treatment
Prior art date
Application number
MA28329A
Other languages
French (fr)
Inventor
Thierry Canton
Laurent Pradier
Jesus Benavides
Hubert Heuer
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA27500A1 publication Critical patent/MA27500A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention a pour objet l'application des inhibiteurs de recapture intestinale de l'acide biliaire pour la prévention et le traitement de la maladie d'Alzheimer, le cas échéant en association avec un inhibiteur de HMG-CoA réductase, un inhibiteur de la capture de cholestérol, un inhibiteur de la synthèse de cholestérol ou un inhibiteur des APP secrétases.The subject of the invention is the application of inhibitors of intestinal reuptake of bile acid for the prevention and treatment of Alzheimer's disease, where appropriate in combination with an inhibitor of HMG-CoA reductase, an inhibitor of cholesterol capture, a cholesterol synthesis inhibitor or an APP secretase inhibitor.

MA28329A 2002-12-12 2005-06-10 PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE MA27500A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (en) 2002-12-12 2002-12-12 APPLICATION OF INTESTINAL BILIARY ACID RECAPTURE INHIBITORS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE

Publications (1)

Publication Number Publication Date
MA27500A1 true MA27500A1 (en) 2005-08-01

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28329A MA27500A1 (en) 2002-12-12 2005-06-10 PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE

Country Status (22)

Country Link
EP (1) EP1572174A1 (en)
JP (1) JP2006514063A (en)
KR (1) KR20050084250A (en)
CN (1) CN1726016A (en)
AR (1) AR042354A1 (en)
AU (1) AU2003296802A1 (en)
BR (1) BR0317280A (en)
CA (1) CA2507945A1 (en)
CO (1) CO5700712A2 (en)
FR (1) FR2848452B1 (en)
HR (1) HRP20050534A2 (en)
MA (1) MA27500A1 (en)
MX (1) MXPA05005556A (en)
NO (1) NO20053341L (en)
NZ (1) NZ540496A (en)
PE (1) PE20040770A1 (en)
PL (1) PL377110A1 (en)
RS (1) RS20050420A (en)
RU (1) RU2005121909A (en)
TW (1) TW200503707A (en)
WO (1) WO2004062652A1 (en)
ZA (1) ZA200504656B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CN1918131B (en) 2004-02-05 2011-05-04 前体生物药物股份公司 Novel inhibitors of glutaminyl cyclase
CA2589102C (en) 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
KR101441725B1 (en) * 2007-05-22 2014-09-18 오츠카 세이야쿠 가부시키가이샤 A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
JP6217938B2 (en) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー Bile acid recirculation inhibitors for the treatment of cholestatic liver disease in children
US20130108573A1 (en) * 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
AU668682B2 (en) * 1991-02-22 1996-05-16 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
EP0910351A1 (en) * 1996-06-27 1999-04-28 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
JP2002501887A (en) * 1998-01-28 2002-01-22 ワーナー−ランバート・カンパニー How to treat Alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (en) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation and medicaments containing these compounds
DE19845405C2 (en) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Aryl-substituted propanolamine derivatives and their use
US20010028895A1 (en) * 2000-02-04 2001-10-11 Bisgaier Charles L. Methods of treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (en) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
PL377110A1 (en) 2006-01-23
AR042354A1 (en) 2005-06-15
ZA200504656B (en) 2006-08-30
KR20050084250A (en) 2005-08-26
HRP20050534A2 (en) 2006-11-30
WO2004062652A1 (en) 2004-07-29
NO20053341D0 (en) 2005-07-08
CA2507945A1 (en) 2004-07-29
CN1726016A (en) 2006-01-25
FR2848452A1 (en) 2004-06-18
BR0317280A (en) 2005-11-08
RS20050420A (en) 2007-04-10
JP2006514063A (en) 2006-04-27
AU2003296802A1 (en) 2004-08-10
CO5700712A2 (en) 2006-11-30
NZ540496A (en) 2008-04-30
NO20053341L (en) 2005-09-07
TW200503707A (en) 2005-02-01
RU2005121909A (en) 2006-01-20
EP1572174A1 (en) 2005-09-14
MXPA05005556A (en) 2005-07-26
PE20040770A1 (en) 2004-12-10
FR2848452B1 (en) 2007-04-06

Similar Documents

Publication Publication Date Title
MA27500A1 (en) PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
ATE443043T1 (en) PHENYLCARBOXAMIDE AS A BETA-SECRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S
GB0223040D0 (en) Therapeutic compounds
TNSN07063A1 (en) THERAPEUTIC USES OF RTP801 INHIBITORS
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
TNSN98155A1 (en) COMBINATIONS OF PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN AND ANTIHYPERTENSITIVE AGENTS, AND PROCESS FOR THEIR PREPARATION
EP1769791A3 (en) Treatment of Alzheimer's disease with cell cycle inhibitors
EA200800880A1 (en) COMBINATION OF ROSIGLITAZONE AND DROPSEEN, INTENDED TO IMPROVE COGNITIVE FUNCTION
NO20065117L (en) Composition comprising a JNK inhibitor and cyclosporin.
DE602004007808D1 (en) NEW GAMMA SECRETASE INHIBITORS
NO20053855L (en) 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases.
IL229124A0 (en) Inhibitors of the mutant form of kit
MY133332A (en) Pyrrolidone derivatives as maob inhibitors
HUP0003852A2 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
HUP0301991A2 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
MXPA05009986A (en) Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders.
MA29531B1 (en) NEW PROCESS FOR TREATING HYPERLIPIDEMIA
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
ATE550039T1 (en) AGENTS FOR THE TREATMENT OF GLOMERULAR DISEASES
WO2004028456A3 (en) Method and composition for treating neurodegenerative disorders
TW200612900A (en) The use of therapeutic and preventive action of l-3-n-butylphthalide on dementia, involving alzheimer's disease and vascular dementia
DE60126504D1 (en) USE OF CANDIDA-EFFECTIVE AGENTS FOR THE TREATMENT OF DISORDERS OF ORAL AND INTESTINAL MUCOSA
WO2002076482A3 (en) USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS